Shionogi Looks Beyond Crestor to HIV Platform

TOKYO - Shionogi still has a few years to reap the benefits of Crestor royalties from AstraZeneca, but the looming generic substitution of rival Lipitor is forcing the company to prepare for a slowdown of its blockbuster drug. But according to Macquarie Equities Research, revised ex-U.S. Crestor prospects, strong pipeline prospects and recent launches could position Shionogi well in the near term